Article by Pharmacy Times

“Officials with the FDA have approved esketamine CIII nasal spray (Spravato, Janssen Pharmaceutical Companies of Johnson & Johnson) for use in conjunction with an oral antidepressant in adults with treatment-resistant depression (TRD). This is the first new mechanism of action in 3 decades to treat major depressive disorder (MDD).1,2

The approval follows a phase 3 clinical trial with more than 1700 adults with TRD. In a short-term study, those who took Spravato and an oral antidepressant experienced superior improvement in depression symptoms at 4 weeks, compared to those who received a placebo and an oral antidepressant. In a long-term study, patients in stable remission taking the medication who continued treatment with the medicine were 51% less likely to relapse versus those who maintained a regimen of a placebo and an oral antidepressant.”

Click here to continue reading this article. 

Enjoy our blog post? Subscribe!

Subscribe to our newsletter and receive the latest news from our team. Learn more about the people behind the prescription, latest events, newest client programs, industry resources, and much more.

Thank you! Please check your email to confirm your subscription and watch for info from us soon!